ENZON INC
8-K, 2000-08-17
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: CHEMFAB CORP, SC TO-T/A, EX-99.D.4, 2000-08-17
Next: GATEFIELD CORP, DEFR14A, 2000-08-17




                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported) August 10, 2000

                                  ENZON, INC.
             (Exact name of registrant as specified in its charter)



         Delaware                          0-12957                  22-237286
(State or other jurisdiction            (Commission               (IRS Employer
     of incorporation)                  File Number)             Identification)



                20 Kingsbridge Road, Piscataway, New Jersey 08854
               (Address of principal executive offices) (Zip Code)



        Registrant's telephone number, including area code (732) 980-4500




          (Former name or former address, if changed since last report)



<PAGE>

Item 5. Other Events

     Enzon, Inc. announced that Peter Tombros, (58), President and CEO of Enzon,
Inc., has signed a new employment  agreement  extending his tenure through 2003.
Mr.  Tombros has advised the Board of  Directors  that he intends to retire upon
completion of this new agreement.  Based on Mr. Tombros' decision, the Board has
decided to  implement  a  succession  plan to ensure  strong  leadership  of the
company upon his departure.

     Certain statements made herein related to potential  government  approvals,
market potential,  commercialization  and sales revenues of medical products and
biologics,  as  well  as  their  therapeutic   applications  and  outcomes,  are
forward-looking  and are made  pursuant  to the safe  harbor  provisions  of the
Securities  Litigation  Reform Act of 1995.  Such  statements  involve risks and
uncertainties,  which  may  differ  materially  from  those  set  forth in these
statements. In addition, the economic, competitive, governmental,  technological
and other factors identified in Enzon's filings with the Securities and Exchange
Commission could affect such results.

                                       2

<PAGE>

                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Dated:   August 17, 2000

             ENZON, INC.
      ------------------------
            (Registrant)


                                         By: /s/ Kenneth J. Zuerblis
                                             -----------------------------------
                                             Kenneth J. Zuerblis
                                             Vice President,
                                             Finance and Chief Financial Officer

                                       3



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission